Home/Pipeline/NTI164

NTI164

Autism Spectrum Disorder

Phase 3Active

Key Facts

Indication

Autism Spectrum Disorder

Phase

Phase 3

Status

Active

Company

Neurotech International, Neurotech International, Neurotech International, Neurotech International

About Neurotech International

Australian‑focused biotech developing a broad‑spectrum oral cannabinoid for paediatric neuroinflammatory disorders.

View full company profile

About Neurotech International

Australian‑focused biotech developing a broad‑spectrum oral cannabinoid for paediatric neuroinflammatory disorders.

View full company profile

About Neurotech International

Australian‑focused biotech developing a broad‑spectrum oral cannabinoid for paediatric neuroinflammatory disorders.

View full company profile

About Neurotech International

Australian‑focused biotech developing a broad‑spectrum oral cannabinoid for paediatric neuroinflammatory disorders.

View full company profile

Therapeutic Areas

Neurology Pediatrics

Other Autism Spectrum Disorder Drugs

Drug	Company	Phase	Status
Exo‑Autism	Advancells	Phase 1	Active
Autism Program	Ignite Biomedical	Discovery	Active
Kingdom Therapeutics Collaboration	Celadon Pharmaceuticals	Pre-clinical	Active
MDXX‑2	PharmAla Biotech	Preclinical	Active
NeuroNOS-1	NeuroNOS	Preclinical	Active
Banked Cord Blood Stem Cells	Cryo-Cell	Clinical Trials	Investigational